Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tourette Syndrome | 7 | 2019 | 37 | 2.610 |
Why?
|
| Movement Disorders | 6 | 2020 | 141 | 1.950 |
Why?
|
| Parkinson Disease | 17 | 2023 | 1164 | 1.770 |
Why?
|
| Tic Disorders | 7 | 2017 | 17 | 1.740 |
Why?
|
| Conversion Disorder | 1 | 2020 | 5 | 0.790 |
Why?
|
| Neurological Rehabilitation | 1 | 2020 | 7 | 0.780 |
Why?
|
| Anxiety | 1 | 2020 | 152 | 0.700 |
Why?
|
| Tremor | 1 | 2020 | 141 | 0.690 |
Why?
|
| Antipsychotic Agents | 3 | 2010 | 82 | 0.680 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 144 | 0.670 |
Why?
|
| Estrogens | 4 | 2003 | 33 | 0.660 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2019 | 23 | 0.620 |
Why?
|
| Humans | 39 | 2023 | 29337 | 0.580 |
Why?
|
| Antiparkinson Agents | 5 | 2004 | 130 | 0.580 |
Why?
|
| Somatoform Disorders | 2 | 2013 | 20 | 0.580 |
Why?
|
| Depression | 1 | 2020 | 465 | 0.570 |
Why?
|
| Male | 25 | 2023 | 15621 | 0.540 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 145 | 0.540 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2019 | 34 | 0.540 |
Why?
|
| Female | 26 | 2023 | 16197 | 0.530 |
Why?
|
| Parents | 1 | 2016 | 105 | 0.530 |
Why?
|
| Hospitalization | 1 | 2017 | 317 | 0.500 |
Why?
|
| Psychotherapy, Psychodynamic | 1 | 2013 | 3 | 0.480 |
Why?
|
| Psychotherapy, Brief | 1 | 2013 | 4 | 0.480 |
Why?
|
| Child | 8 | 2017 | 1346 | 0.450 |
Why?
|
| Placebo Effect | 1 | 2013 | 25 | 0.450 |
Why?
|
| Psychophysiologic Disorders | 1 | 2012 | 8 | 0.420 |
Why?
|
| Supranuclear Palsy, Progressive | 3 | 2006 | 44 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 340 | 0.400 |
Why?
|
| Middle Aged | 14 | 2020 | 9823 | 0.370 |
Why?
|
| Adolescent | 9 | 2017 | 2279 | 0.370 |
Why?
|
| Body Weight | 1 | 2010 | 133 | 0.370 |
Why?
|
| Complementary Therapies | 1 | 2009 | 15 | 0.360 |
Why?
|
| Cerebral Cortex | 3 | 2004 | 195 | 0.360 |
Why?
|
| Sialorrhea | 2 | 2009 | 5 | 0.340 |
Why?
|
| Adult | 11 | 2020 | 8601 | 0.340 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 1113 | 0.330 |
Why?
|
| Indans | 1 | 2008 | 9 | 0.320 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2008 | 16 | 0.320 |
Why?
|
| Piperidines | 1 | 2008 | 32 | 0.320 |
Why?
|
| Young Adult | 4 | 2020 | 1932 | 0.320 |
Why?
|
| Adrenal Medulla | 1 | 2007 | 31 | 0.310 |
Why?
|
| Brain | 5 | 2011 | 1689 | 0.310 |
Why?
|
| Inpatients | 2 | 2020 | 141 | 0.310 |
Why?
|
| Neurodegenerative Diseases | 2 | 2000 | 117 | 0.310 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 195 | 0.300 |
Why?
|
| Estradiol | 2 | 2004 | 58 | 0.290 |
Why?
|
| Aged | 14 | 2020 | 9448 | 0.270 |
Why?
|
| Dopamine | 4 | 2006 | 156 | 0.260 |
Why?
|
| Cholinergic Fibers | 1 | 2004 | 6 | 0.250 |
Why?
|
| Prosencephalon | 1 | 2004 | 8 | 0.250 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 20 | 0.250 |
Why?
|
| Sex Factors | 2 | 2023 | 496 | 0.250 |
Why?
|
| Educational Status | 2 | 2017 | 295 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 437 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 194 | 0.240 |
Why?
|
| Aging | 3 | 2004 | 1593 | 0.230 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 78 | 0.230 |
Why?
|
| Levodopa | 2 | 2004 | 142 | 0.220 |
Why?
|
| Neurologic Examination | 2 | 2000 | 146 | 0.220 |
Why?
|
| Thiazoles | 1 | 2002 | 35 | 0.220 |
Why?
|
| Sex Characteristics | 1 | 2023 | 132 | 0.210 |
Why?
|
| Tyrosine 3-Monooxygenase | 3 | 2007 | 83 | 0.200 |
Why?
|
| Hypoxia, Brain | 1 | 2001 | 14 | 0.200 |
Why?
|
| Myoclonus | 1 | 2001 | 29 | 0.200 |
Why?
|
| Menstrual Cycle | 1 | 2000 | 27 | 0.200 |
Why?
|
| Sensory Aids | 1 | 2000 | 3 | 0.190 |
Why?
|
| Apomorphine | 1 | 2000 | 37 | 0.190 |
Why?
|
| Basal Ganglia Diseases | 1 | 2000 | 11 | 0.190 |
Why?
|
| Muscle Rigidity | 1 | 2000 | 26 | 0.190 |
Why?
|
| Speech | 1 | 2000 | 27 | 0.180 |
Why?
|
| Kuru | 1 | 1999 | 2 | 0.180 |
Why?
|
| Cues | 1 | 2000 | 61 | 0.180 |
Why?
|
| Mood Disorders | 1 | 2019 | 31 | 0.180 |
Why?
|
| Child, Preschool | 3 | 2010 | 642 | 0.180 |
Why?
|
| Animals | 6 | 2012 | 4552 | 0.180 |
Why?
|
| Double-Blind Method | 3 | 2014 | 503 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 1999 | 59 | 0.170 |
Why?
|
| Polypharmacy | 1 | 1998 | 10 | 0.170 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 1442 | 0.170 |
Why?
|
| Hyperkinesis | 1 | 1998 | 11 | 0.160 |
Why?
|
| Cameroon | 1 | 2017 | 2 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1830 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 12 | 0.160 |
Why?
|
| Academic Performance | 1 | 2017 | 5 | 0.160 |
Why?
|
| Brain Diseases | 1 | 1998 | 82 | 0.160 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 35 | 0.150 |
Why?
|
| Morbidity | 1 | 2017 | 63 | 0.150 |
Why?
|
| Walking | 1 | 2000 | 252 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 50 | 0.150 |
Why?
|
| Ataxia | 1 | 1997 | 79 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 324 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 188 | 0.140 |
Why?
|
| Time Factors | 2 | 2013 | 1616 | 0.140 |
Why?
|
| Disability Evaluation | 1 | 2017 | 327 | 0.130 |
Why?
|
| Comorbidity | 2 | 2008 | 498 | 0.130 |
Why?
|
| Age Factors | 1 | 2017 | 843 | 0.130 |
Why?
|
| Ubiquinone | 1 | 2014 | 3 | 0.130 |
Why?
|
| Antioxidants | 1 | 2014 | 56 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2006 | 156 | 0.120 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 11 | 0.120 |
Why?
|
| Ovariectomy | 2 | 2004 | 26 | 0.110 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 254 | 0.110 |
Why?
|
| Autopsy | 2 | 2007 | 335 | 0.110 |
Why?
|
| Dystonic Disorders | 1 | 2012 | 29 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2014 | 3478 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 56 | 0.100 |
Why?
|
| Neurons | 2 | 2006 | 374 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 1997 | 1011 | 0.090 |
Why?
|
| HIV Infections | 1 | 2017 | 970 | 0.090 |
Why?
|
| Dopamine Agents | 2 | 2000 | 40 | 0.090 |
Why?
|
| Cholinergic Antagonists | 2 | 2000 | 13 | 0.090 |
Why?
|
| Primary Dysautonomias | 1 | 2009 | 5 | 0.090 |
Why?
|
| Basal Ganglia | 2 | 1999 | 29 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2006 | 1184 | 0.080 |
Why?
|
| Salivary Glands | 1 | 2007 | 4 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2010 | 428 | 0.080 |
Why?
|
| Videotape Recording | 2 | 1998 | 43 | 0.080 |
Why?
|
| Chromogranin A | 1 | 2007 | 13 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2014 | 1811 | 0.080 |
Why?
|
| Cell Survival | 1 | 2007 | 169 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 173 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2008 | 394 | 0.070 |
Why?
|
| Head | 1 | 2006 | 24 | 0.070 |
Why?
|
| Myositis | 1 | 2006 | 23 | 0.070 |
Why?
|
| Awareness | 1 | 2006 | 37 | 0.070 |
Why?
|
| Multiple System Atrophy | 1 | 2006 | 42 | 0.070 |
Why?
|
| Substantia Nigra | 2 | 2006 | 148 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 162 | 0.060 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2004 | 14 | 0.060 |
Why?
|
| Macaca mulatta | 1 | 2004 | 65 | 0.060 |
Why?
|
| Reference Values | 2 | 2006 | 227 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2004 | 14 | 0.060 |
Why?
|
| Dyskinesias | 1 | 2004 | 35 | 0.060 |
Why?
|
| Risk Factors | 1 | 2010 | 2443 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2004 | 46 | 0.060 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2003 | 16 | 0.060 |
Why?
|
| Aspartic Acid | 1 | 2003 | 15 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 42 | 0.060 |
Why?
|
| Synaptic Transmission | 2 | 2002 | 46 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2006 | 1221 | 0.050 |
Why?
|
| Biological Availability | 1 | 2002 | 26 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2002 | 20 | 0.050 |
Why?
|
| Carbidopa | 1 | 2002 | 45 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 67 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2002 | 66 | 0.050 |
Why?
|
| Postmenopause | 1 | 2002 | 61 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2002 | 112 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 145 | 0.050 |
Why?
|
| Drug Implants | 1 | 2001 | 11 | 0.050 |
Why?
|
| Progesterone | 1 | 2000 | 26 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2006 | 1939 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2006 | 4851 | 0.050 |
Why?
|
| Larynx | 1 | 2000 | 16 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2001 | 58 | 0.050 |
Why?
|
| New Guinea | 1 | 1999 | 2 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2000 | 60 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 451 | 0.040 |
Why?
|
| Video Recording | 1 | 1999 | 47 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2000 | 100 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 117 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2000 | 109 | 0.040 |
Why?
|
| Neck Muscles | 1 | 1998 | 13 | 0.040 |
Why?
|
| Peripheral Nerve Injuries | 1 | 1998 | 16 | 0.040 |
Why?
|
| Methysergide | 1 | 1998 | 7 | 0.040 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1998 | 12 | 0.040 |
Why?
|
| London | 1 | 1998 | 3 | 0.040 |
Why?
|
| Serotonin Antagonists | 1 | 1998 | 19 | 0.040 |
Why?
|
| Rats | 1 | 2001 | 854 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1998 | 23 | 0.040 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1998 | 4 | 0.040 |
Why?
|
| Stereotypic Movement Disorder | 1 | 1998 | 4 | 0.040 |
Why?
|
| Dystonia | 1 | 1998 | 53 | 0.040 |
Why?
|
| Antisocial Personality Disorder | 1 | 1998 | 9 | 0.040 |
Why?
|
| Psychomotor Agitation | 1 | 1998 | 14 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 553 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 1998 | 40 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 324 | 0.040 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1997 | 3 | 0.040 |
Why?
|
| Prion Diseases | 1 | 1997 | 3 | 0.040 |
Why?
|
| Treatment Failure | 1 | 1998 | 159 | 0.040 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1998 | 54 | 0.040 |
Why?
|
| Prevalence | 1 | 1999 | 487 | 0.040 |
Why?
|
| Vasculitis | 1 | 1997 | 32 | 0.040 |
Why?
|
| Atrophy | 1 | 1997 | 102 | 0.040 |
Why?
|
| Lymphoma | 1 | 1997 | 44 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 1998 | 86 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2013 | 638 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 1997 | 125 | 0.040 |
Why?
|
| Shoulder Injuries | 1 | 1998 | 139 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 124 | 0.040 |
Why?
|
| Disease Progression | 1 | 1999 | 787 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 389 | 0.040 |
Why?
|
| Patient Care Team | 1 | 1998 | 140 | 0.040 |
Why?
|
| Astrocytes | 1 | 1997 | 122 | 0.040 |
Why?
|
| Gait | 1 | 2000 | 404 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 959 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 2 | 2006 | 13 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 65 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 1942 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 391 | 0.030 |
Why?
|
| Spain | 1 | 2013 | 18 | 0.030 |
Why?
|
| United States | 1 | 1998 | 2333 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 1999 | 3273 | 0.020 |
Why?
|
| PubMed | 1 | 2009 | 12 | 0.020 |
Why?
|
| Constipation | 1 | 2009 | 21 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 44 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 788 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 13 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 42 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 20 | 0.020 |
Why?
|
| Electromyography | 1 | 2006 | 78 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 99 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 234 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 1 | 2006 | 181 | 0.020 |
Why?
|
| alpha-Synuclein | 1 | 2006 | 138 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2004 | 118 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 26 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 349 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 126 | 0.010 |
Why?
|
| Motor Skills | 1 | 2003 | 61 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 78 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 108 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2003 | 71 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 770 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 355 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 678 | 0.010 |
Why?
|
| Motor Activity | 1 | 2004 | 369 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 495 | 0.010 |
Why?
|
| Biomarkers | 1 | 2002 | 689 | 0.010 |
Why?
|
| Torsion Abnormality | 1 | 1998 | 10 | 0.010 |
Why?
|
| Accidents, Traffic | 1 | 1998 | 14 | 0.010 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 1998 | 6 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1998 | 19 | 0.010 |
Why?
|
| Botulinum Toxins | 1 | 1998 | 32 | 0.010 |
Why?
|
| Posture | 1 | 1998 | 78 | 0.010 |
Why?
|
| Shoulder Joint | 1 | 1998 | 572 | 0.010 |
Why?
|